Search Term or Code: Advanced Search 
Geek Mode

Measure: CMS153

Chlamydia Screening for Women

Measure Versions

eMeasure Code Measure Year Full Version Number Title
CMS153v12 2024 12.0.000 Chlamydia Screening in Women
CMS153v11 2023 11 Chlamydia Screening for Women
CMS153v10 2022 10.0.000 Chlamydia Screening for Women
CMS153v9 2021 9.2.000 Chlamydia Screening for Women
CMS153v8 2020 8.1.000 Chlamydia Screening for Women
CMS153v7 2019 7.4.000 Chlamydia Screening for Women
CMS153v6 2018 6.2.000 Chlamydia Screening for Women
CMS153v5 2017 5.0.000 Chlamydia Screening for Women


Percentage of women 16-24 years of age who were identified as sexually active and who had at least one test for chlamydia during the measurement period


Codes to identify sexually active women include codes for: pregnancy, sexually transmitted infections, contraceptives or contraceptive devices, and infertility treatments. The denominator exclusion does not apply to patients who qualify for the initial population (IP) based on services other than the pregnancy test alone. These other services include services for sexually transmitted infections, contraceptives or contraceptive devices and infertility treatments. For example, a patient who has both a pregnancy test and a chlamydia diagnosis, either of which would qualify them for the IP, would not be eligible for this denominator exclusion. Patient self-report for procedures as well as diagnostic studies should be recorded in 'Procedure, Performed' template or 'Diagnostic Study, Performed' template in QRDA-1. Patient self-report is not allowed for laboratory tests. This eCQM is a patient-based measure. This version of the eCQM uses QDM version 5.5. Please refer to the eCQI resource center ( for more information on the QDM.

Patient Group Definitions

Group Description Instructions Links
Initial PopulationWomen 16 to 24 years of age who are sexually active and who had a visit in the measurement periodWebchart Instructions
DenominatorEquals Initial PopulationWebchart Instructions
Denominator ExclusionsWomen who are only eligible for the initial population due to a pregnancy test and who had an x-ray or an order for a specified medication within 7 days of the pregnancy test. Exclude patients whose hospice care overlaps the measurement period.Webchart Instructions
NumeratorWomen with at least one chlamydia test during the measurement periodWebchart Instructions
Numerator ExclusionsNot ApplicableWebchart Instructions
Denominator ExceptionsNone


Full eMeasure Code eMeasure Identifier Measure Year Version NQF # GUID
CMS153v9 153 2021 9.2.000 Not Applicable c9930664-be3d-4ffe-ae4a-5cf4933ecb89
Steward Developer Endorsed By
National Committee for Quality Assurance National Committee for Quality Assurance
Scoring Method Measure Type Stratification Risk Adjustment
Proportion PROCESS Report a total score, and each of the following strata: Stratum 1: Patients age 16-20 Stratum 2: Patients age 21-24 None

Rate Aggregation


Improvement Notation

Higher score indicates better quality


Chlamydia trachomatis is the most common sexually transmitted bacterial infection in the U.S., resulting in roughly 1.7 million cases (Centers for Disease Control and Prevention, 2018). Chlamydia infections are often asymptomatic, but, if left untreated, can lead to serious and irreversible complications (U.S. Preventive Services Task Force, 2014; Centers for Disease Control and Prevention, 2018). Women are particularly vulnerable when infected with chlamydia. Left untreated, chlamydia can cause pelvic inflammatory disease (PID), which can lead to chronic pelvic pain or infertility. Pregnant women may also transmit the infection to their infant, potentially resulting in neonatal pneumonia (Centers for Disease Control and Prevention, 2018).

Clinical Recommendation Statement

U.S. Preventive Services Task Force (2014):
The task force recommends screening for chlamydia in sexually active females aged 24 years or younger and in older women who are at increased risk for infection (B recommendation)



Transmission Format


Applicable Value Sets

Category Value Set OID
Assessment, Performed Sexually Active 2.16.840.1.113883.3.464.1003.121.12.1040
Diagnosis Carrier of Predominantly Sexually Transmitted Infection 2.16.840.1.113883.3.464.1003.112.11.1023
Diagnosis Chlamydia 2.16.840.1.113883.3.464.1003.112.12.1003
Diagnosis Complications of Pregnancy, Childbirth and the Puerperium 2.16.840.1.113883.3.464.1003.111.12.1012
Diagnosis Genital Herpes 2.16.840.1.113883.3.464.1003.110.12.1049
Diagnosis Gonococcal Infections and Venereal Diseases 2.16.840.1.113883.3.464.1003.112.12.1001
Diagnosis HIV 2.16.840.1.113883.3.464.1003.120.12.1003
Diagnosis Inflammatory Diseases of Female Reproductive Organs 2.16.840.1.113883.3.464.1003.112.12.1004
Diagnosis Other Female Reproductive Conditions 2.16.840.1.113883.3.464.1003.111.12.1006
Diagnosis Syphilis 2.16.840.1.113883.3.464.1003.112.12.1002
Diagnostic Study, Order Diagnostic Studies During Pregnancy 2.16.840.1.113883.3.464.1003.111.12.1008
Diagnostic Study, Order X-Ray Study (all inclusive) 2.16.840.1.113883.3.464.1003.198.12.1034
Encounter, Performed Encounter Inpatient 2.16.840.1.113883.3.666.5.307
Encounter, Performed Home Healthcare Services 2.16.840.1.113883.3.464.1003.101.12.1016
Encounter, Performed Office Visit 2.16.840.1.113883.3.464.1003.101.12.1001
Encounter, Performed Preventive Care - Established Office Visit, 0 to 17 2.16.840.1.113883.3.464.1003.101.12.1024
Encounter, Performed Preventive Care Services - Established Office Visit, 18 and Up 2.16.840.1.113883.3.464.1003.101.12.1025
Encounter, Performed Preventive Care Services-Initial Office Visit, 18 and Up 2.16.840.1.113883.3.464.1003.101.12.1023
Encounter, Performed Preventive Care- Initial Office Visit, 0 to 17 2.16.840.1.113883.3.464.1003.101.12.1022
Intervention, Order Hospice care ambulatory 2.16.840.1.113762.1.4.1108.15
Intervention, Performed Hospice care ambulatory 2.16.840.1.113762.1.4.1108.15
Laboratory Test, Order Lab Tests During Pregnancy 2.16.840.1.113883.3.464.1003.111.12.1007
Laboratory Test, Order Lab Tests for Sexually Transmitted Infections 2.16.840.1.113883.3.464.1003.110.12.1051
Laboratory Test, Order Pap Test 2.16.840.1.113883.3.464.1003.108.12.1017
Laboratory Test, Order Pregnancy Test 2.16.840.1.113883.3.464.1003.111.12.1011
Laboratory Test, Performed Chlamydia Screening 2.16.840.1.113883.3.464.1003.110.12.1052
Medication, Active Contraceptive Medications 2.16.840.1.113883.3.464.1003.196.12.1080
Medication, Order Contraceptive Medications 2.16.840.1.113883.3.464.1003.196.12.1080
Medication, Order Isotretinoin 2.16.840.1.113883.3.464.1003.196.12.1143
Patient Characteristic Ethnicity Ethnicity 2.16.840.1.114222.4.11.837
Patient Characteristic Payer Payer 2.16.840.1.114222.4.11.3591
Patient Characteristic Race Race 2.16.840.1.114222.4.11.836
Patient Characteristic Sex Female 2.16.840.1.113883.3.560.100.2
Patient Characteristic Sex ONC Administrative Sex 2.16.840.1.113762.1.4.1
Procedure, Performed Delivery Live Births 2.16.840.1.113883.3.464.1003.111.12.1015
Procedure, Performed Procedures During Pregnancy 2.16.840.1.113883.3.464.1003.111.12.1009
Procedure, Performed Procedures Involving Contraceptive Devices 2.16.840.1.113883.3.464.1003.111.12.1010


Centers for Disease Control and Prevention (CDC). (2019). Sexually Transmitted Disease Surveillance 2018. Atlanta: U.S. Department of Health and Human Services.
LeFevre, M. L., & U.S. Preventive Services Task Force. (2014). Screening for Chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. Annals of Internal Medicine, 161(12), 902–910.


The performance Measure is not a clinical guideline and does not establish a standard of medical care, and has not been tested for all potential applications. THE MEASURE AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND. Due to technical limitations, registered trademarks are indicated by (R) or [R] and unregistered trademarks are indicated by (TM) or [TM].


This Physician Performance Measure (Measure) and related data specifications are owned and were developed by the National Committee for Quality Assurance (NCQA). NCQA is not responsible for any use of the Measure. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. NCQA holds a copyright in the Measure. The Measure can be reproduced and distributed, without modification, for noncommercial purposes (e.g., use by healthcare providers in connection with their practices) without obtaining approval from NCQA. Commercial use is defined as the sale, licensing, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain. All commercial uses or requests for modification must be approved by NCQA and are subject to a license at the discretion of NCQA. (C) 2012-2019 National Committee for Quality Assurance. All Rights Reserved. 

Limited proprietary coding is contained in the Measure specifications for user convenience. Users of proprietary code sets should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any third party codes contained in the specifications.

CPT(R) contained in the Measure specifications is copyright 2004-2019 American Medical Association. LOINC(R) copyright 2004-2019 Regenstrief Institute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright 2004-2019 International Health Terminology Standards Development Organisation. ICD-10 copyright 2019 World Health Organization. All Rights Reserved.